ZOVIRAX VIRAL RESISTANCE POTENTIAL IS PRIMARY ISSUE TO BE ADDRESSED BY FDA
This article was originally published in The Tan Sheet
Executive Summary
ZOVIRAX VIRAL RESISTANCE POTENTIAL IS PRIMARY ISSUE TO BE ADDRESSED BY FDA in reviewing Burroughs Wellcome's Rx-to-OTC switch application for the treatment of recurrent genital herpes, FDA's Nonprescription Drugs and Antiviral Drugs Advisory Committees agreed at a joint May 19 meeting held after a public hearing on the switch. The issue of vital resistance topped a list of issues prepared by the two committees for FDA in reviewing the Zovirax (acyclovir) switch application and in preparing for the joint advisory committee's review in July.